Literature DB >> 17169842

Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function.

Matthew Campbell1, Ross Collery, Alice McEvoy, Tom A Gardiner, Alan W Stitt, Brenda Brankin.   

Abstract

PURPOSE: This study aimed to evaluate the effects of endostatin on tight junction (TJ) integrity in retinal microvascular endothelial cells (RMECs) in vitro and in vivo. Moreover, it was hypothesized that endostatin-induced occludin upregulation regulated VEGF165-mediated increases in endothelial cell permeability and involved activation of the MAPK signaling cascade. Endostatin is a 20-kDa fragment of collagen XVIII that has been shown to be efficacious in the eye by preventing retinal neovascularization. Endostatin is a specific inhibitor of endothelial cell proliferation, migration, and angiogenesis and has been reported to reverse VEGF-mediated increases in vasopermeability and to promote integrity of the blood-retinal barrier (BRB). In order to determine the mechanism of endostatin action on BRB integrity, we have examined the effects of endostatin on a number of intracellular pathways implicated in endothelial cell physiology.
METHODS: C57/Bl6 mice were injected with VEGF165 and/or endostatin, and the distribution of occludin staining was determined using retinal flatmounts. Western blot analysis of RMECs treated with VEGF165 and/or endostatin was used to determine changes in occludin expression and p38 MAPK and extracellular regulated kinase (ERK1/ERK2 MAPK) activation, while FD-4 flux across the RMEC monolayer was used to determine changes in paracellular permeability.
RESULTS: Endostatin prevented the discontinuous pattern of occludin staining observed at the retinal blood vessels of mice administered an intraocular injection of VEGF165. It was shown that endostatin activated p38 MAPK 5 min after addition to RMECs and continued to do so for approximately 30 min. Endostatin was also shown to activate ERK1/ERK2 5 min after addition and continued to do so, albeit with less potency, up to and including 15 min after addition. Inhibition of p38 MAPK and ERK1/ERK2 prevented endostatin's ability to upregulate levels of occludin expression. Inhibition of these key signaling molecules was shown to prevent endostatin's ability to protect against VEGF165-mediated increases in paracellular permeability in vitro. However, it appears that p38 MAPK may play a more important role in VEGF-mediated permeability, as inhibition of ERK1/ERK2 will not prevent VEGF165-mediated permeability compared with control (untreated) cells or cells treated with both a p38 MAPK inhibitor and VEGF165.
CONCLUSIONS: Occludin is important for the maintenance of tight junction integrity in vivo. In a p38 MAPK and ERK1/ERK2 dependent manner, endostatin was shown to upregulate the levels of expression of the tight junction protein occludin. Inhibition of these key MAPK components may prevent endostatin's ability to decrease VEGF165-induced paracellular permeability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17169842     DOI: 10.1080/02713680601013025

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  13 in total

1.  An experimental platform for systemic drug delivery to the retina.

Authors:  Matthew Campbell; Anh T H Nguyen; Anna-Sophia Kiang; Lawrence C S Tam; Oliviero L Gobbo; Christian Kerskens; Sorcha Ni Dhubhghaill; Marian M Humphries; G-Jane Farrar; Paul F Kenna; Peter Humphries
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

2.  Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation.

Authors:  Rana Al-Sadi; Shuhong Guo; Dongmei Ye; Karol Dokladny; Tarik Alhmoud; Lisa Ereifej; Hamid M Said; Thomas Y Ma
Journal:  J Immunol       Date:  2013-05-08       Impact factor: 5.422

3.  A peptide derived from laminin-γ3 reversibly impairs spermatogenesis in rats.

Authors:  Linlin Su; Dolores D Mruk; Pearl P Y Lie; Bruno Silvestrini; C Yan Cheng
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

4.  [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].

Authors:  I Lüdeke; P Terheyden; S Grisanti; M Lüke
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

5.  A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.

Authors:  Manas R Biswal; Howard M Prentice; C Kathleen Dorey; Janet C Blanks
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-06       Impact factor: 4.799

6.  The radiosensitization effects of Endostar on human lung squamous cancer cells H-520.

Authors:  Zhen Y You; Yong Zhao; Feng Liu; Ying D Zhang; Jun J Wang
Journal:  Cancer Cell Int       Date:  2010-05-24       Impact factor: 5.722

7.  Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.

Authors:  Jean-Claude A Marshall; Joshua W Collins; Joji Nakayama; Christine E Horak; David J Liewehr; Seth M Steinberg; Mary Albaugh; Fernando Vidal-Vanaclocha; Diane Palmieri; Maryse Barbier; Maximilien Murone; Patricia S Steeg
Journal:  J Natl Cancer Inst       Date:  2012-08-21       Impact factor: 13.506

8.  Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.

Authors:  Celina García; Jorge Aranda; Edith Arnold; Stéphanie Thébault; Yazmín Macotela; Fernando López-Casillas; Valentín Mendoza; Hugo Quiroz-Mercado; Hebert Luis Hernández-Montiel; Sue-Hwa Lin; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

9.  Endostatin is protective against monocrotaline-induced right heart disease through the inhibition of T-type Ca(2+) channel.

Authors:  Keisuke Imoto; Sayaka Kumatani; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  Pflugers Arch       Date:  2016-03-29       Impact factor: 3.657

10.  Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis.

Authors:  Ganna Tolstanova; Xiaoming Deng; Tetyana Khomenko; Pallavi Garg; Brankica Paunovic; Longchuan Chen; Shanthi V Sitaraman; Joseph Shiloach; Sandor Szabo; Zsuzsanna Sandor
Journal:  Life Sci       Date:  2010-11-01       Impact factor: 6.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.